An experimental immunotherapy involving so-called natural killer cells elicited complete remissions in a majority of patients with advanced Hodgkin lymphoma, researchers reported Sunday.
In the study, eight of the 13 patients given an optimized dose and schedule of the therapy saw their tumor cells completely disappear with minimal side effects. The new data improve upon initial results presented last year, although it remains unclear how long the responses will last.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
